Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 3/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.37 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556188 | 0.81 | MKNK1 (0.39) | RIPK2MKNK1MTORGRM5CYP2A6 | |
| SCHEMBL12410399 | 0.81 | MKNK1 (0.44) | RIPK2MKNK1MTORGRM5CYP2A6 | |
| SCHEMBL12410501 | 0.80 | MKNK1 (0.38) | RIPK2MKNK1MTORGRM5CYP2A6 | |
| SCHEMBL12410569 | 0.78 | CYP2A6 (0.42) | RIPK2MKNK1MTORGRM5CYP2A6 | |
| SCHEMBL251938 | 0.78 | ASIC3 (0.42) | RIPK2MKNK1MTORGRM5CYP2A6 | |
| SCHEMBL12410406 | 0.78 | CYP2A6 (0.42) | RIPK2MKNK1MTORGRM5CYP2A6 | |
| SCHEMBL12410469 | 0.77 | MKNK1 (0.41) | RIPK2MKNK1MTORGRM5CYP2A6 | |
| SCHEMBL1554591 | 0.77 | GRM5 (0.46) | RIPK2MKNK1GRM5CYP2A6GRM4 | |
| SCHEMBL18567903 | 0.76 | GRM2 (0.46) | RIPK2MKNK1MTOR | |
| SCHEMBL12410482 | 0.75 | ADORA2A (0.36) | RIPK2MKNK1MTORGRM5CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9066518-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9066518-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| EP-2488030-B1 | 1-(PYRID-3-YL)-PYRAZOLES AND 1-(PYRIMID-5-YL)-PYRAZOLES AS PEST CONTROLLERS | BAYER CROPSCIENCE AG (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20140221362-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221362-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20110166143-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166143-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2011045224-A1 | 1- (PYRID-3-YL) -PYRAZOLE AND 1- (PYRIMID-5-YL) -PYRAZOLE AS PESTICIDE | BAYER CROPSCIENCE AG (DE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221362-A1 | Heterocyclic Compounds as Pesticides | DDT, ACHE, BCHE | RIPK2 1635/4885MKNK1 2220/4885MTOR 2193/4885 |
| US-20110166143-A1 | Heterocyclic Compounds as Pesticides | DDT, ACHE, BCHE | RIPK2 1635/4885MKNK1 2220/4885MTOR 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.